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Abstract 
Background: Chronic malaria is usually defined as a long-term malarial infection in semi-immune subjects, usually 
without fever or other acute symptoms. The untreated infection may evolve to hyper-reactive malarial splenomegaly 
(HMS), a life-threatening complication. This paper describes the largest series of HMS ever observed outside endemic 
countries, and the clinical outcome after a single anti-malarial treatment. Contrarily to most authors, still reporting the 
traditional, long-term treatment, regardless possible further exposure, the patients in this series did not receive any 
further prophylaxis if they were not re-exposed to malaria infection.
Methods: A retrospective, longitudinal study, describing all patients with HMS diagnosed at the Centre for Tropi-
cal Diseases of Negrar, Verona, took place over a 25-year period. HMS was defined by a longitudinal spleen diameter 
≥16 cm, IgM ≥ 2.5 g/L, anti-malarial antibody titre ≥160, exclusion of other causes of splenomegaly. The short-term 
(≤6 months) clinical outcome after a single anti-malarial treatment was analysed and so was the long-term outcome 
of subjects re-exposed to malaria and submitted or not to anti-malarial prophylaxis or intermittent treatment. The 
association of the outcome with the main independent variables was first assessed with univariate analysis. Logistic 
regression was also performed.
Results: Forty-four subjects with HMS were retrieved. Of those with a short-term follow-up visit (<6 months, median 
43 days) available before returning to endemic areas, 20/22 resulted improved/cured, two were unchanged. Of 22 
expatriates seen at long-term follow-up after re-exposure, 18 were improved/cured, including eight out of nine who 
had followed an anti-malarial prophylaxis and 10/13 who had opted for the alternative of an intermittent treatment.
Conclusion: HMS is the most severe form of chronic malaria. A single anti-malarial treatment is probably adequate 
to treat HMS in the absence of re-exposure, while an adequate prophylaxis is necessary for patients exposed again to 
malaria transmission. Intermittent treatment would probably be the only viable approach in endemic countries.
© 2016 Bisoffi et al. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Chronic malaria is a long-term infection in semi-immune 
subjects. It is usually characterized by the absence of fever 
or any other acute symptoms, so that this condition has 
long been defined as asymptomatic carriage of malaria 
parasites [1]. However, it has been argued recently that 
asymptomatic malaria does not exist [2], as the chronic 
presence of malaria parasites is a cause of anaemia, pre-
disposes to other infections, and is a common cause of 
maternal complications, to cite only some of the prob-
lems related to chronic malaria carriage.
Hyper-reactive malarial splenomegaly (HMS) is prob-
ably the most severe form of chronic malaria [3]. The 
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main characteristics of the syndrome have been sum-
marized in a recent review [4]. Overwhelming infections 
are a major cause of death in these patients, and the syn-
drome is characterized by high mortality if not properly 
treated. Malaria microscopy is often negative in these 
patients, leading researchers to speculate that the pro-
gression of the syndrome is not related to the presence 
of malaria infection in blood, but rather to an immune-
mediated mechanism. However, it has been observed 
recently that more sensitive diagnostic methods, such 
as quantitative buffy coat (QBC), rapid diagnostic tests 
(RDTs) or polymerase chain reaction (PCR), may yield 
a positive result in microscopically negative patients [4, 
5]. Moreover, a single anti-malarial treatment has been 
able to cure the syndrome according to a few anecdotal 
reports [6]. In addition, long-term chloroquine prophy-
laxis, historically the mainstay of treatment of HMS 
by virtue of its immune-modulating properties [7], has 
apparently become less effective in recent years, in face of 
widespread resistance by Plasmodium falciparum to this 
molecule.
A previous paper [8] described the characteristics of 
‘early HMS’ (e-HMS), a condition that was not previ-
ously considered, as it does not fulfill the case definition 
criteria of HMS, but that is at risk of evolving into ‘full-
blown HMS’ if left untreated. This paper describes the 
main characteristics of all patients with full-blown HMS 
(mostly Italian expatriates, but also immigrants) seen 
in the last 25  years at the Centre for Tropical Diseases 
(CTD) of Negrar, Verona, Italy.
The main objectives of the present study were: (a) to 
describe the main clinical and laboratory findings of 
immigrants and expatriates diagnosed at CTD with HMS; 
(b) to analyse the short-term and long-term outcome 
of HMS patients after a single anti-malarial treatment, 
followed by long-term prophylaxis (or by intermittent 





The clinical records of patients were retrieved as 
described previously [8], covering the period from 1 
January, 1990 to 3 September, 2015 (date of the last 
follow-up visit of the last patient). Briefly, patients with 
splenomegaly or with raised IgM and with anti-malarial 
antibody titre ≥160 (IFAT-Biomérieux) were retrieved 
from the CTD patient database. Patients meeting the 
case definition of full-blown HMS as outlined below were 
included, while the remaining subjects, meeting the ten-
tative case definition of e-HMS (spleen diameter <16 cm 
and/or normal IgM), that were the object of the previous 
study, were excluded. Patients were then traced prospec-
tively for any further visit short term (≤6 months) or long 
term (>6 months).
The following case definition for HMS was used:
 – antimalarial antibody titre (IFAT-Biomérieux) ≥1/160, 
PLUS:
  – massive splenomegaly (ultrasound longitudinal diam-
eter, corresponding to spleen length, ≥16 cm) (normal 
value in healthy adults 8–11 cm) [9];
  – IgM level ≥2 SD above the local mean (or ≥2.5  g/L 
according to the local laboratory);
 – no other identifiable cause of splenomegaly or of raised 
IgM, such as schistosomiasis, cirrhosis, haematological 
conditions, and others as described previously [8].
Final outcome was assessed on the basis of the last fol-
low up visit.
Data entry and data elaboration
Data were exported to a pre-structured Excel file, includ-
ing the main epidemiological, clinical and laboratory 
findings as well as the results of an ultrasound scan, as 
available at baseline (T1), short-term follow-up (T2) and 
long-term follow-up (T3) [8].
Definition of follow‑up criteria
  – Cured: absence of splenomegaly and normal IgM 
value;
  – Improved: ≥1 cm decrease of the spleen diameter, or 
unchanged spleen diameter and ≥1  g/dL decrease of 
IgM level;
  – Unchanged: <1 cm or no variation of the spleen diam-
eter and <1 g/dL or no variation of IgM level;
  – Progressed: ≥1 cm increase of the spleen diameter, or 
unchanged spleen diameter and ≥1  g/dL increase of 
IgM level.
Laboratory methods for malaria detection
Thick and thin film microscopy, as well as the QBC 
Malaria Test (QBC Diagnostics Inc, Philipsburg, USA), 
were performed following the routine procedures of 
the CTD laboratory. This is a referral laboratory for 
parasitic infections in Italy, where slides for quality 
control of laboratories of different Italian regions are 
prepared. Although no specific quality assessment of 
microscopy for the study purpose was performed (as 
is obvious in a retrospective study), quality control, 
including intra- and inter-observer reproducibility, is 
systematically carried out according to standardized, 
certified procedures.
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Treatment and prophylaxis
All patients were treated with a single anti-malarial, as 
for an acute malaria, once the diagnosis was established. 
The standard regimen followed at CTD was with oral 
quinine, 10 mg/kg × 3 for 3 days, followed by pyrimeth-
amine–sulfametopyrazine (Metakelfin®) single dose [10], 
until the year 2002, then with artemisinin-based combi-
nation therapy (ACT), regimen currently in use. No fur-
ther treatment or prophylaxis was indicated for patients 
remaining in Italy, while for those returning to endemic 
countries, a prophylaxis was indicated with doxycycline, 
and with mefloquine as a second choice. As a possible 
alternative for those not wishing to take a prophylaxis 
for a long time, an intermittent treatment was advised, 
empirically suggesting a periodicity of at least a full anti-
malarial course every 3 months during the low-transmis-
sion season, and every month in the high-transmission 
season. Patients were advised to follow the first-line regi-
men for uncomplicated malaria of the host country.
Statistical analysis
STATA IC 14 (StataCorp, 4905 Lakeway, College Sta-
tion, TX, USA) was used for data analysis. For categori-
cal variables the absolute and relative frequencies were 
calculated. For continuous variables, the median and IQ 
range were considered. The association between categor-
ical variables was evaluated using the χ2 test. The Fisher 
exact test was used if appropriate. Uncertainty was quan-
tified using a significance value of 0.05. Logistic regres-
sion was performed to study the potential association of 
the independent variables (outcomes) with the potential 
independent predictors.
Ethical issues
Data were entered anonymously in the database. The 
competent Ethics Committee (Comitato Etico delle prov-
ince di Verona e Rovigo) acknowledged the study proto-




Figure 1 shows the patient flow. From the database of 171 
patients with splenomegaly and high anti-malarial anti-
body titre, 126 were classified as e-HMS [8], and were 
excluded from the analysis. One record, initially classified 
as a full-blown HMS, was then discarded as a thorough 
scrutiny of the patient clinical data raised the suspicion of 
a previously unrecognized liver cirrhosis. The remained 
44 records were analysed.
Thirty-six patients were expatriates from non-
endemic countries (one Mexican and 35 Italian) and 
eight were African immigrants. Seven expatriates and 
three immigrants were not seen again, while 29 and five, 
respectively, had at least one follow-up visit. Several 
patients had more than one follow-up visit, coinciding 
with periodical returns to Italy.
At least one short-term follow-up visit (≤6  months) 
before any further exposure to malaria, was available for 
half of the patients of both groups (18/36 expatriates, 
4/8 immigrants). At least one long-term follow-up visit 
(>6 months) was available for 23/36 expatriates (of whom 
22 had been re-exposed to malaria), and for only one 
immigrant (with an unclear history of re-exposure). The 
main symptoms, signs and laboratory findings of expa-
triate and immigrant patients at their first contact are 
summarized in Table  1. The spleen measure was based 
on ultrasound for all but three patients, for whom an 
estimation based on physical examination was done (not 
included in Table 1).
Most of the subjects were symptomatic at presentation 
(Table  1). Fever (usually low-grade), asthenia, intestinal 
discomfort and pain at the left upper abdominal quadrant 
were the most frequent symptoms recorded. No signifi-
cant difference was found between the two main ethnic 
groups for most of the symptoms. Asthenia was reported 
by more than half of the expatriates (18/35 or 51 %) ver-
sus only 1/7 immigrants (14  %) (p  =  0.059). Hepato-
megaly (usually moderate) was found in 23/43 subjects 
(53  %), 21/35 expatriates (67  %) and 2/8 immigrants 
(25 %), respectively (p = 0.118). For one subject (expatri-
ate) the data on symptoms and signs were incomplete.
Parasite detection
A search for malaria parasites was carried out for 32/36 
Italian subjects (89 %), and 6/8 immigrants (75 %), with a 
positive result in 17/32 (53 %) and 5/6 (71 %), respectively 
(p = 0.370). The parasite density was low or very low in 
most cases (Table 2). Of the 38 cases for which data were 
recorded, 16 (42  %) resulted negative, nine (24  %) were 
positive at QBC only, and nine more had a parasite den-
sity (as quantified at thick film) below 500 parasites/μL. 
Only one case had a parasite density higher than 2000 
parasites/μL. Of the 38 subjects with a malaria search 
carried out, fever was present in 7/15 (47 %) of those with 
a negative result and in 16/23 (70 %) of those with a posi-
tive result (p  =  0.283). In particular, fever was present 
in all the four subjects with a parasite density >500/μL, 
while it was lacking in 7/19 (37 %) of those with a lower 
parasite density and in 5/9 (56 %) of those with parasites 
found at QBC only.
Short‑term outcome
Twenty-four subjects had a short-term follow-up visit 
(<6  months after treatment and with no re-exposure 
in between). The median time elapsed between initial 
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and follow-up visit was 45.5  days (IQ range 66). One 
subject was impossible to classify as the spleen diam-
eter was unchanged and the IgM value at follow-up was 
not available, while for another subject there was no 
recorded assessment of the spleen measure at follow-up. 
The results of the remaining 22 subjects are reported in 
Table  3. Most had improved, and none had worsened. 
The reduction of the spleen size over time (as recorded 
for all the subjects who had an echography measurement 
available at baseline and follow-up) is plotted in Fig. 2.
Fig. 1 Patient flow diagram
Table 1 Main characteristics of subjects diagnosed with HMS, immigrants and expatriates
a Info on symptoms lacking for one patient








Age years; median (IQ range) 56.1 (15.8) 58.6 (10.0) 27.4 (14.2) 0.0001
Gender (F/M) 15/29 10/26 5/3 0.099
Exposure, years; median (IQ range) 20.0 (13.0) 20.0 (12.0) 27.5 (12.0) 0.2278
Presence of symptoms; ratio Y/Na 42/1 34/1 8/0 1.000
Fever; ratio Y/N* 24/19 19/16 5/3 1.000
Asthenia; ratio Y/N* 19/24 18/17 1/7 0.059
Left upper q. pain; ratio Y/Na 9/34 6/29 3/5 0.332
Intestinal discomfort ratio Y/Na 12/31 11/24 1/7 0.407
Spleen diameter in cm; median (IQ range) 18.0 (3.3) 18.0 (3.3) 17.6 (3.5) 0.5643
Hepatomegaly; ratio Y/Na 23/20 21/14 2/6 0.118
Hb, mg/dL normal 12–16; median (IQ range) 10.0 (3.0) 9.6 (2.2) 11.6 (4.0) 0.1695
RBC × 106/µL, n 4.2–5.4; median (IQ range) 3.4 (1.0) 3.3 (0.9) 4.0 (1.1) 0.0239
Plt × 103/µL, n 130–400; median (IQ range) 138.0 (81.0) 128.0 (76.0) 178.5 (100.0) 0.0702
ESR mm/h, n < 25; median (IQ range) 57.5 (43.5) 59.0 (38.0) 51.0 (86.0) 0.7352
IgM, g/L, n < 2.5; median (IQ range) 6.4 (3.9) 6.8 (3.8) 5.0 (12.6) 0.9738
Plasmodium in blood; ratio Y/Nb 22/16 17/15 5/1 0.370
Improved at T1; ratio Y/N 20/2 16/2 4/0 1.000
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Long‑term outcome
Twenty-four subjects had at least one long-term follow-
up visit and a reliable history concerning re-exposure or 
not to malaria. The median time elapsed between the ini-
tial and the last visit was 4.12 years (IQ range 2.77). Only 
two subjects had not been re-exposed. One was a 27 years 
old immigrant woman from Ghana, first observed in 
March 1993, who never returned to her country and 
was last seen after 3 years, when she was perfectly cured 
(with an initial spleen longitudinal diameter of 17 cm and 
a final one of 11  cm). The other was an expatriate mis-
sionary sister aged 63 when she was first seen in March 
2001, with a huge spleen (24 cm, described as occupying 
most of the abdomen), showing nevertheless a significant 
improvement over time, with a 6-cm reduction of the 
longitudinal spleen diameter and a normalization of IgM 
when she was last seen in April 2004. Both had received 
a standard anti-malarial treatment at the first encounter, 
with no further prophylaxis. The results of the remaining 
22 patients are summarized in Table 4. All were expatri-
ates. Of the nine subjects reporting having followed the 
recommended anti-malarial prophylaxis (usually doxycy-
cline), eight were improved or cured, and so were 10/13 
subjects not reporting a prophylaxis, but an intermittent 
treatment instead (p = 0.616). Of the independent poten-
tial predictors included in the logistic regression model 
(including age, gender, symptoms, and in particular fever, 
presence of malaria parasites in blood, prophylaxis) none 
was significantly associated with the short-term or long-
term outcome.
Case description
The main findings of two particularly informative cases 
are briefly outlined below.
Case 1
Italian, female, non-governmental organization, vol-
unteer in Cameroon, consulted for the first time in 
November 1996, when 57 years old. She had lived in the 
African country for 22  years. She presented with low-
grade fever and a profound asthenia. The liver was mod-
erately enlarged, while the spleen longitudinal diameter 
was 18 cm (she was 155 cm high). The laboratory showed 
marked anaemia (red blood cells (RBC), 2.67 ×  106/μL, 
Haemoglobin (Hb) 7.7 g/L) and leucopaenia (white blood 
cells (WBC), 2.17  ×  103/μL), a moderately low platelet 
count (PLT, 92  ×  103/μL), raised lactic-dehydrogenase 
(LDH) (747 U/L, N  <  250), and IgM (4.7  g/L, N  <  2.5). 
Both the thick and thin film for malaria were negative, 
but the QBC showed very scanty trophozoites, compat-
ible with P. falciparum. The anti-malarial antibody titre 
(IFAT, BioMérieux) was ≥160 (not further diluted). She 
was treated with quinine, 10 mg/kg ×  3/day for 3 days, 
followed by a single dose of pyrimethamine–sulfametox-
azole, the standard regimen for acute malaria at that time 
Table 2 Malaria parasites in blood
p = 0.410, Fisher’s exact
a Negative blood films, parasites found at QBC only
Parasitaemia (N/µL) All Expatriates Immigrants
Negative 16 (42 %) 15 (47 %) 1 (17 %)
QBCa 9 (24 %) 7 (22 %) 2 (33 %)
1–500/µL 9 (24 %) 6 (19 %) 3 (50 %)
501–2000/µL 3 (8 %) 3 (9 %) 0 (0 %)
>2000/µL 1 (2 %) 1 (3 %) 0 (0 %)
Total 38 32 6
Table 3 Outcome at  the first follow-up visit for  subjects 
not re-exposed to malaria (N. 22), according to nationality
p = 1.000, Fisher’s exact
Outcome Expatriates Immigrants Total
Cured or improved 16 4 20
Unchanged 2 0 2
Total 18 4 22
Fig. 2 The reduction of the spleen size over time (short-term out-
come)
Table 4 Outcome at  the last follow-up visit for  subjects 
re-exposed to  malaria (N. 22), according to  the reported 
prophylaxis or intermittent treatment
p = 0.616, Fisher’s exact
Outcome Prophylaxis Intermittent  
treatment
Total




Total 9 13 22
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at CTD [10]. A short-term follow-up was not possible as 
the patient insisted on returning to the host country for 
urgent matters, but she agreed to follow a strict proph-
ylaxis with doxycycline and to return for a follow-up as 
early as possible. In fact, she represented after almost 
1  year, in November 1997. She reported having been 
compliant with the prophylaxis advised and feeling much 
better. The spleen diameter had decreased to 13 cm, the 
main laboratory findings had greatly improved, and the 
IgM were now normal (1.4  g/L). However, in consid-
eration of the previous findings, she was advised not to 
return to Cameroon, but she did not follow the advice 
and presented again at CTD 2½ years later (April 2000). 
This time she had not followed any prophylaxis, nor the 
alternative advice of an intermittent treatment, due to 
concern for toxicity. She showed a marked progression, 
with similar symptoms as at presentation, a spleen diam-
eter of 19  cm, IgM 5.6, and other laboratory findings 
similar to the first visit, but for a negative malaria thick 
film and QBC. She was treated for malaria again, and 
returned to Cameroon despite contrary advice.
Case 2
Italian, male, Catholic missionary in Uganda for 27 years, 
64 years old, consulted CTD in August 1998 for a medi-
cal check-up while he was on home leave. He reported a 
long history of acute malaria episodes, while in the last few 
years he said that he had often had malaria “without fever”. 
He identified the latter condition on the basis of “typi-
cal symptoms” (mainly a profound weakness), and took a 
short course of quinine when this occurred. The remaining 
clinical history was negative. He declared not having any 
particular complaint at presentation. The physical exami-
nation revealed a moderate hepatomegaly and a marked 
splenomegaly, with the lower pole well beyond the umbili-
cal line and an echografic longitudinal diameter of 21 cm. 
The laboratory findings were similar to the previous case, 
with RBC 3.5 × 106/μL, WBC 4.84 × 103/μL, PLT 145 103/
μL, bilirubin 25.5 μmol/L, LDH 553 U/L, and IgM 9.2 g/L. 
Both the thick and thin film for malaria were negative, 
and so was the QBC. The anti-malarial antibody titre was 
10,240. He was treated with the same regimen as Case 1. 
Shortly afterwards he had to go back to Uganda, therefore 
a short-term follow-up was not possible. An anti-malarial 
prophylaxis was recommended, either with doxycycline or 
with mefloquine (he had already taken the latter drug for 
treatment with no side effects). It was proposed the patient 
should come back to follow-up on his next return to Italy, 
initially planned in 1  year, considering that a long-term 
anti-malarial prophylaxis was not generally recommended 
because of potential toxicity. Nevertheless, he returned to 
medical observation after almost 5 years (July 2003), dur-
ing which he reported having regularly taken one tablet of 
mefloquine once a week for the whole of the 5 years, and 
declared that he had “never been healthier”. The spleen 
diameter had decreased by 4 cm and the blood cell count, 
as well as the IgM value (0.33 g/L), were normal.
Discussion
This paper describes the largest series ever published of 
HMS in a non-endemic country. The spleen measure 
required for case definition of HMS has been variable [4]. 
Most papers until recently have relied on physical exami-
nation. Many authors have reported following Fakunle’s 
criteria, requiring a spleen size bigger than 10 cm below 
the costal margin. Others based the spleen size assess-
ment on Hackett’s criteria [11], usually requiring at least a 
Hackett’s Grade II (spleen palpable, but not beyond a hor-
izontal line halfway between the costal margin and umbil-
icus). Only a few papers have used an ultrasound scan to 
measure the spleen length, with a minimal longitudinal 
diameter to define HMS ranging from 15 cm [5] to 18 cm 
[6]. In this paper, the minimal diameter required for the 
case definition of the full-blown HMS is 16 cm, although 
patients with a smaller spleen size have also shown a ten-
dency to progression [8]. Moreover, virtually all studies, 
including this one, have not related the spleen measure to 
the patient’s size, which is obviously a limitation.
The study population: symptoms, signs, laboratory 
findings
Most of the study subjects (36) were Italians, mostly 
missionary people, while there were eight immigrants. 
The only important difference between the two popula-
tions was the median age as immigrants are on average 
younger people, compared to expatriates who have spent 
decades in a foreign country. Asthenia and hypersplen-
ism (with a lower median RBC and platelet count) were 
more common in expatriates, while the two populations 
were similar in all other respects (although the immigrant 
patient population was too small to detect less marked 
differences). Most patients were symptomatic at presen-
tation, although symptoms were usually vague, similarly 
reported in literature [4]. Fever (almost invariably low-
grade) was present in more than half of the subjects, and 
did not appear to be significantly correlated to the pres-
ence of malaria parasites in blood, although it was pre-
sent in all the four patients with a parasite density over 
500/μL. Parasitaemia was low or very low in all subjects, 
with only one case with >2000 parasites/μL (roughly cor-
responding to 0.05  %), and one quarter of the positive 
subjects having malaria parasites only identified at QBC. 
Although for positive patients an acute malaria in semi-
immune subjects cannot be entirely excluded, the simi-
larity in all other respects between positive and negative 
subjects, and the very low, average parasite density in the 
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former, makes this hypothesis unlikely. The patient popu-
lation appears to represent a continuum, with malaria 
parasites possibly present in most or all patients, but at a 
density too low to be detected for some of them.
Outcome
All patients were treated with a single anti-malarial treat-
ment, similar to acute malaria. In no case was a prolonged 
regimen at prophylactic dose administered, unless/until 
the patient eventually returned to a malaria-endemic coun-
try. Patients were always advised to avoid re-exposure and 
to choose a non-malarious country/area for residence if 
returning abroad, but this advice was rarely followed. In 
case of re-exposure, an effective anti-malarial prophylaxis 
(taking into account the drug-resistance profile of the 
country) was strongly recommended, as it was considered 
that the risk of progression of the syndrome outweighed 
that of the drug’s side effects. The short-term outcome 
of most of the subjects assessed after treatment, in the 
absence of re-exposure, was favourable, with a compara-
tively quick decrease of the spleen size (Fig.  2). The time 
elapsed between treatment and short-term follow-up was 
generally quite short (6 weeks on average), although identi-
cal to the largest series published so far in a non-endemic 
country [6]. In studies carried out in endemic countries, 
the follow-up time has been very variable, ranging from 
1  month to 2  years [4]. With a longer interval, possibly a 
higher proportion of patients would have been completely 
cured at follow-up. On the other hand, anecdotal reports 
indicate that patients with HMS and no re-exposure could 
improve or heal, even without treatment [12]. It may well 
be possible that this would have occurred in the patients 
of the present series, provided that they remained unex-
posed for a sufficient time to spontaneously clear malaria 
parasites. The outcome was also favourable for most of 
the subjects seen again after a variable period of time of 
re-exposure to malaria (Table 4). All but one of those who 
declared having adhered to the recommended prophylaxis 
were cured or had improved, and so were most of those 
who had not adhered to prophylaxis, but had followed the 
alternative recommendation of an intermittent treatment. 
Case 1, however, suggests that re-exposure, in the absence 
of prophylaxis or intermittent treatment, is likely to trigger 
the relapse of the syndrome in a much shorter time than the 
long exposure to malaria usually required to develop HMS. 
On the contrary, Case 2 avoided any re-infection with a 
very long-term prophylaxis with mefloquine (declaring 
no side effects) and did not have any relapse. In the other 
cases, the prophylactic regimen used was with doxycycline.
Chronic malaria and HMS
The term ‘chronic malaria’ has usually been used to define 
asymptomatic or pauci-symptomatic carriers of malaria 
parasites in blood [13–15]. However, it has recently been 
argued that asymptomatic malaria does not exist, and the 
presence of Plasmodia in blood, regardless of the presence 
or absence of acute symptoms and of fever in particular, 
should be sufficient to define chronic malaria as a disease 
warranting treatment [2]. HMS can be considered the 
most severe form of chronic malaria, although often with 
negative malaria blood tests. Moreover, the risk of evolu-
tion of a milder splenomegaly (with or without malaria 
parasites found in blood), defined as early-HMS, to a full-
blown HMS has recently been suggested [8]. Splenomeg-
aly (of any size) has been considered as a proxy for malaria 
parasitaemia for years and the ‘spleen rate’ has been used 
as a surrogate for malaria prevalence surveys [16]. If it 
is accepted that patients with chronic malaria should be 
treated, then splenomegalic patients in malaria-endemic 
areas should also be presumptively treated, even in the 
absence of a positive malaria microscopy or RDT.
How to treat chronic malaria and HMS
Evidence in the past few years [4] and from the present 
series suggests that the constant presence of malaria par-
asites in blood is necessary to trigger, as well as to sus-
tain, the syndrome, contrary to the traditional view that 
HMS, once established, does not require the presence 
of Plasmodium and tends to evolve, if untreated, similar 
to an auto-immune disease. According to the traditional 
view, long-term use of chloroquine works as an immune-
modulating drug, rather than an anti-malarial [7]. In this 
series, all patients were treated with a single anti-malarial 
treatment, as for an acute malaria attack, and regardless 
the result of malaria search. No long-term prophylaxis 
was administered to those who did not return to endemic 
countries. For those patients who had planned to return 
to the host, malaria-endemic country, the prophylac-
tic regimen advised was doxycycline, with mefloquine 
as a second choice. Chloroquine was never advised, due 
to the widespread resistance to this drug. It seems clear 
then that the apparent response to prophylaxis observed 
in most patients was due to the prevention of malaria 
infection, and not to ‘immune modulation’. However, a 
long-term (or even life-long) prophylaxis is practically 
not feasible in endemic countries. An intermittent anti-
malarial treatment would be a logical alternative, as it has 
been already extensively used for some at-risk categories 
such as pregnant women and children [17, 18].
Study limitations
This study was retrospective, and for this reason follow-
up data are incomplete and very variable in time. A recall 
bias is likely to have occurred, and therefore the details 
of prophylaxis or intermittent treatment should be taken 
with caution. A selection bias cannot be excluded either 
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and some patients, especially of the first years, may have 
been missed. The potential problems of the case definition 
have been discussed above. PCR for malaria is not used 
at CTD for routine diagnosis, therefore this information 
is lacking for our patients. It is possible that some of the 
cases with negative blood films and QBC would have been 
found positive by the more sensitive PCR. It has recently 
been suggested by McGregor et al. [5] that subjects with 
a positive PCR would be more likely to respond to ther-
apy than negative subjects, indicating a role of molecular 
diagnosis in the case definition of the syndrome. In their 
series of seven patients, only three subjects that did not 
respond to therapy had negative blood films and PCR, 
seemingly indicating that the syndrome requires the pres-
ence of Plasmodium in blood. So the Authors suggest that 
a negative PCR predicts a treatment failure. On the other 
hand, in the present and much larger series most of the 
patients improved at follow-up, and among those who 
didn’t, some had positive malaria films or QBC.
Conclusion
The hyper-reactive malarial splenomegaly (HMS) is the 
most severe form of chronic malaria, and not a different 
disease. A single anti-malarial treatment is sufficient to 
cure/improve most cases. However, reinfection must be 
prevented or immediately treated. As a lifelong prophy-
laxis does not appear to be feasible in malaria-endemic 
countries, considering the high number of chronic 
malaria carriers and patients with splenomegaly, research 
is needed in order to evaluate the efficacy of intermittent 
treatment as well as its best periodicity.
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